Atara Biotherapeutics Inc (ATRA)

$10.1

+0.09

(+0.95%)

Market is closed - opens 8 PM, 08 Nov 2024

Performance

  • $9.89
    $10.38
    $10.10
    downward going graph

    2.05%

    Downside

    Day's Volatility :4.72%

    Upside

    2.73%

    downward going graph
  • $4.97
    $39.50
    $10.10
    downward going graph

    50.84%

    Downside

    52 Weeks Volatility :87.43%

    Upside

    74.43%

    downward going graph

Returns

PeriodAtara Biotherapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
34.12%
1.4%
0.0%
6 Months
-33.59%
3.8%
0.0%
1 Year
-69.91%
15.3%
0.0%
3 Years
-97.73%
11.4%
-27.4%

Highlights

Market Capitalization
58.3M
Book Value
-$22.61
Earnings Per Share (EPS)
-39.0
PEG Ratio
0.0
Wall Street Target Price
90.5
Profit Margin
-290.2%
Operating Margin TTM
-62.41%
Return On Assets TTM
-57.48%
Return On Equity TTM
-2014.86%
Revenue TTM
62.4M
Revenue Per Share TTM
12.26
Quarterly Revenue Growth YOY
2892.7%
Gross Profit TTM
63.6M
EBITDA
-162.1M
Diluted Eps TTM
-39.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-7.53
EPS Estimate Next Year
-8.77
EPS Estimate Current Quarter
-1.56
EPS Estimate Next Quarter
-5.25

Analyst Recommendation

Buy
    61%Buy
    30%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Atara Biotherapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
4
4
4
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 796.04%

Current $10.10
Target $90.50

Technicals Summary

Sell

Neutral

Buy

Atara Biotherapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
29.6%
-33.59%
-69.91%
-97.73%
-97.04%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.01%
-15.81%
-1.7%
31.13%
150.21%
Biontech Se
Biontech Se
-12.27%
17.34%
4.17%
-56.04%
478.94%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
2.34%
76.9%
60.41%
45.24%
198.24%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.04%
20.33%
30.51%
156.8%
152.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
NA
NA
0.0
-7.53
-20.15
-0.57
NA
-22.61
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.49
20.54
1.22
44.74
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-2.99
-0.03
-0.02
NA
85.17
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.87
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.27
0.19
-0.03
0.12
NA
60.66
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
Buy
$66.0M
-97.04%
NA
-290.2%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$91.1B
150.21%
20.49
33.61%
Biontech Se
Biontech Se
Buy
$26.5B
478.94%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.8B
198.24%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.6B
152.08%
32.84
-4.51%

Insights on Atara Biotherapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 5 quarters, 957.0K → 28.64M (in $), with an average increase of 48.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -697.97M → -190.49M (in $), with an average increase of 57.5% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.4% return, outperforming this stock by 130.3%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 45.8% return, outperforming this stock by 143.6%

Institutional Holdings

  • Redmile Group, LLC

    7.97%
  • EcoR1 Capital, LLC

    7.17%
  • Citadel Advisors Llc

    4.59%
  • Bank of America Corp

    3.28%
  • Vanguard Group Inc

    2.98%
  • Centiva Capital LP

    2.47%

Company Information

we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have

Organization
Atara Biotherapeutics Inc
Employees
165
CEO
Dr. Anhco Nguyen Ph.D.
Industry
Health Technology

FAQs